According to Dr. Andrew Bomback, the ACCOLADE study is the largest trial of individuals with this rare kidney condition for whom there are no approved medications, even though the number of patients in the research is too small to draw definitive findings.
FREMONT, CA: ChemoCentryx, a biopharmaceutical company, announced that it presented research results from its Phase III ADVOCATE trial, as well as its Phase II ACCOLADE and LUMINA-1 trials, at the ERA-EDTA (European Renal Association, 'European Dialysis and Transplant Association') annual meeting, held in Berlin, Germany from June 5-8, 2021.
Dr. David Jaynes' presentation The Effect of Avacopan, a Complement C5a Receptor Inhibitor, on Kidney Function in Patients with ANCA-Associated Vasculitis with Renal Disease was named one of the top 10 abstracts of the entire Congress by the ERA-EDTA Paper Selection Committee. Dr. Jayne presented data from the Phase III ADVOCATE trial, which showed that Avacopan treatment resulted in a greater recovery in estimated Glomerular Filtration Rate (eGFR), a key measure of kidney function, and a faster improvement in the urine albumin-to-creatinine ratio than prednisone, with the potential to reduce long-term risks of ANCA vasculitis and renal failure and death.
Orally Administered C5aR Inhibitor Avacopan in a Randomized, Double Blind, Placebo-Controlled Study for Treatment of C3G Glomerulopathy was also highlighted in a late-breaking clinical study presentation. At 26 weeks, he stated that the data indicated that Avacopan had an effect, with a mean improvement in disease activity and substantial improvements in disease chronicity and eGFR compared to the placebo group.
A Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study (LUMINA-1) to Evaluate the Safety and Efficacy of CCX140 in Subjects with Focal Segmental Glomerulosclerosis (FSGS), given by Dr. Frank Cortazar, was the third abstract given at ERA-EDTA. ChemoCentryx has no plans to continue developing CCX140 in FSGS.